Director, HTA, Value & Evidence (HV&E), PCOA
Develops and executes patient-centered outcomes assessment (PCOA) strategies in clinical trials and observational studies to support regulatory approval, market access, and reimbursement. Leads cross-functional collaboration with R&D, CMO, RWE, and Commercial teams, ensuring alignment with global regulatory and HTA requirements. Provides technical leadership in clinical outcome assessment (COA) methodology, evidence generation, and stakeholder engagement across Pfizer’s innovative therapy portfolio.